AGA and Varia Ventures launched the GI Opportunity Fund to invest in fast-growing, early-stage companies in the GI space. In conjunction with the AGA Center for GI Innovation and Technology, the fund speeds innovations from concept to clinic for the benefit of patients with digestive disease.
Through our fund, GIs can join AGA to invest in fast-growing, early stage companies that are transforming care for patients with digestive disease. Many of your colleagues have already invested in the AGA GI Opportunity Fund.
If you are interested, it is time to take action — while the fund is still open.
Congratulations to Virgo, EndoSound and NeXtGen Biologics
- Virgo is an AI-fueled endoscopy capture and clinical trials program.
- EndoSound is the system that transforms any endoscope into an EUS.
- NeXtGen Biologics has patent-protected technology using the tissue of the axolotl (a salamander with regenerative abilities) as an extracellular matrix for a variety of clinical benefits.